The price of medicines has a direct impact on patients, particularly those undergoing long-term or expensive treatment. While the Maximum Retail Price (MRP) is printed on medicine packaging, concerns have increasingly been raised about the significant difference between the price at which medicines are supplied to retailers and the MRP ultimately charged to patients. The Supreme Court recently raised serious concerns over such pricing disparities while hearing petitions relating to the regulation of medicine prices, generic medicines, medical devices and prescription practices. The Court questioned why medicines could carry an MRP several times higher than the price at which they are supplied to retailers. It also examined the consequences of such pricing practices when medicines are purchased in hospitals and the cost is subsequently reimbursed under government healthcare schemes. During the hearing, Justice Sandeep Mehta observed that where a medicine costing substantially less is billed at a much higher amount and the amount is subsequently reimbursed from a government health scheme, the burden ultimately falls on taxpayers. The Court described such a situation as a “clear-cut case of fraud” on its face. However, these observations were made during the hearing of pending petitions and should not be understood as a final adjudication on the legality of every instance of medicine pricing or hospital billing. What Was the Supreme Court Hearing About? The Supreme Court was hearing petitions concerning various issues relating to medicine pricing and healthcare practices. The proceedings included concerns regarding: Pricing of medicines; Difference between manufacturer or retailer price and MRP; Regulation of non-scheduled medicines; Generic medicines; Medical devices; Prescription practices; Pricing practices of hospitals; and The impact of medicine prices on patients and public healthcare schemes. The Bench comprising Justice Vikram Nath and Justice Sandeep Mehta examined whether the existing regulatory framework adequately addresses substantial disparities between the price at which medicines are supplied and the MRP printed on them. The matter has been listed for further submissions on 29 September 2026. Why Did the Supreme Court Question the MRP of Medicines? One of the central concerns raised during the hearing was the substantial difference between the price at which a medicine is supplied to a retailer and the MRP printed on the medicine. The Court questioned why a medicine supplied to a retailer at a significantly lower price could carry an MRP many times higher. For example, the hearing referred to a situation where a medicine supplied for approximately ₹2,700 could carry an MRP of ₹27,000. The Court questioned whether such a large disparity should be permissible and whether there should be a mechanism to limit the difference between the actual supply price and the MRP. How Does MRP Affect Patients? MRP is important because it represents the maximum price at which a packaged product can ordinarily be sold to the consumer, subject to the applicable legal framework. In the case of medicines, however, patients may not always have the practical ability to compare prices. A patient admitted to a hospital may require medicines immediately. In many situations, the patient or their family members may have limited choices regarding where the medicine is purchased. This becomes particularly relevant where hospitals require patients to purchase medicines from the hospital's own pharmacy or store. During the hearing, concerns were raised that patients may be required to purchase medicines from hospital stores at the full MRP even when the same medicine may be available elsewhere at a substantially lower price. Corporate Hospitals and In-House Pharmacies The Court's observations came in the context of submissions concerning corporate hospitals and their pharmacy practices. The petitioner submitted that corporate hospitals may require patients to purchase medicines from their own hospital stores. According to the submissions, this can create a situation where patients do not have the same freedom to compare prices that they may have while purchasing medicines from an ordinary retail pharmacy. The petitioner also argued that hospitals may sometimes refuse to take responsibility for administering medicines purchased from outside pharmacies. This issue was presented as particularly significant for patients who require immediate treatment and therefore may not have a practical opportunity to search for cheaper alternatives. Why Did the Court Refer to Government Healthcare Schemes? The Court also considered the implications of inflated medicine prices where treatment is funded through government healthcare schemes. Under schemes such as Ayushman Bharat, eligible patients can receive healthcare benefits subject to the applicable scheme conditions. The Court observed that where a hospital receives reimbursement for medicines at an inflated price, the financial burden may ultimately be borne by public funds. This led Justice Sandeep Mehta to observe that if a medicine which should cost substantially less is billed at a much higher amount and the hospital receives reimbursement, the ultimate burden falls on taxpayers. The Court therefore viewed the issue not merely as a private transaction between a hospital and a patient but also as a matter involving public expenditure where government-funded healthcare schemes are involved. What Is the Difference Between Scheduled and Non-Scheduled Medicines? The proceedings also involved discussion regarding the existing system of medicine price regulation. Under the Drugs (Prices Control) Order, 2013 (DPCO), certain medicines are subject to price control mechanisms, including ceiling prices for medicines included in the relevant schedule. The petitioners raised concerns regarding medicines that are not covered by the same ceiling-price mechanism. According to the submissions made before the Court, the initial price fixation of non-scheduled medicines is not regulated in the same manner as scheduled medicines. The petitioners argued that this can contribute to significant differences between the price at which medicines are supplied and the MRP ultimately printed on them. The precise scope of price regulation and the adequacy of the existing framework are among the issues being examined in the pending proceedings. Can Manufacturers Print Any MRP They Want? This issue also came up during the hearing. The Court questioned the justification for permitting an MRP that is several times higher than the actual price at which the medicine is supplied. The discussion highlighted an important aspect of the pricing chain: the relationship between the manufacturer's price, the price charged to stockists and retailers, and the final MRP. The petitioner argued that manufacturers may print the MRP while the actual financial burden on patients arises at the retail or hospital level. On the other hand, submissions were also made that the pricing structure needs to be examined across the entire supply chain rather than attributing the issue to only one participant. The Court's questions indicate that the pricing mechanism itself is being examined in the ongoing proceedings. Why Did the Court Raise Concerns About Heavy Discounts? The Court also discussed another unusual aspect of medicine pricing. Suppose a medicine has an MRP of ₹5,000 but is routinely sold for ₹2,000 or less. A patient may naturally question why the printed MRP is so much higher than the actual selling price. The Court observed that such large differences can affect consumer confidence. Unlike ordinary consumer goods, medicines are generally purchased because they are medically required. Patients may therefore have less ability to treat price comparison as a normal purchasing decision. Can Patients Always Buy Medicines From Another Pharmacy? This depends on the circumstances. In ordinary retail transactions, consumers may compare prices between different pharmacies before purchasing a medicine. However, the situation can be different in hospitals. During the hearing, it was submitted that some hospitals may require patients to purchase medicines through their own pharmacy or hospital store. This raises questions concerning patient choice, transparency in billing and the reasonableness of the pricing structure. Whether particular hospital practices are legally permissible will depend on the facts, applicable regulations, contractual arrangements and the findings ultimately made by the Court or competent authorities. What Is the Role of the National Pharmaceutical Pricing Authority? The National Pharmaceutical Pricing Authority (NPPA) plays an important role in implementing and monitoring pharmaceutical price regulation under the applicable framework. The broader regulatory system deals with issues such as: Ceiling prices for specified medicines; Monitoring of medicine prices; Price revisions; Compliance with applicable pricing requirements; and Enforcement of applicable price-control provisions. The proceedings before the Supreme Court have raised questions about whether the existing framework sufficiently addresses the pricing of medicines that fall outside the scheduled price-control mechanism. What About Generic Medicines? The hearing also involved discussion concerning generic medicines. The petitioner submitted that prescribing medicines by generic name could potentially reduce treatment costs, but also raised concerns regarding the choice of manufacturer when a doctor does not prescribe a specific brand. The argument was that if only the generic formulation is prescribed, the pharmacist may effectively decide which manufacturer's product is supplied to the patient. Questions concerning the quality, reliability and availability of medicines were also raised. The Court considered these issues alongside the larger question of medicine pricing and patient choice. What Should Patients Check on a Medicine Bill? Patients and their family members should carefully examine hospital medicine bills, particularly when substantial amounts are involved. It is useful to check: Name of the medicine. Strength and dosage. Quantity supplied. MRP printed on the packaging. Price charged in the bill. Applicable discounts, if any. Batch number. Expiry date. GST details, wherever applicable. Whether the medicine was actually supplied. Whether the medicine was returned but the amount was not adjusted. Whether the billing corresponds with the treatment records. Patients should preserve the original bills and medicine packaging wherever a dispute arises. What Can a Patient Do If There Is a Dispute Regarding Medicine Billing? If a patient believes that they have been incorrectly charged or that a hospital has engaged in an unfair billing practice, they should first obtain complete documentation. Important documents may include: Hospital bills; Pharmacy invoices; Prescriptions; Discharge summary; Medicine strips or packaging; Payment receipts; Treatment records; Details of the medicine's MRP; Correspondence with the hospital; and Any written response received from the hospital. Depending on the nature of the dispute, a patient may explore appropriate remedies under consumer protection law or other applicable regulatory mechanisms. Where the issue involves a broader pricing or regulatory violation, the appropriate government authority may also need to be approached. Is Charging the Full MRP Automatically Illegal? Not necessarily. The Supreme Court's remarks in the present hearing concern the broader issue of significant disparities between supply prices and MRPs and their consequences. A hospital or retailer charging an amount within the legally permissible MRP does not automatically establish fraud merely because the acquisition price was lower. The legality of a particular transaction depends on the applicable law, pricing regulations, nature of the medicine, billing practice and other relevant facts. The Court's observations should therefore be understood in the context of the specific issues being examined in the pending proceedings. What Could Be the Impact of the Supreme Court Proceedings? The ongoing proceedings could have implications for the regulation of medicine pricing if the Court ultimately issues directions or makes findings concerning the existing regulatory framework. Possible areas of significance include: Greater transparency in medicine pricing; Regulation of excessive price disparities; Patient access to reasonably priced medicines; Transparency in hospital pharmacy billing; Government reimbursement under healthcare schemes; Regulation of non-scheduled medicines; Generic medicine prescriptions; and Pricing of medical devices. However, the final position will depend upon the Court's eventual orders and the submissions of the parties. Key Takeaways The Supreme Court has raised serious concerns over large disparities between medicine supply prices and MRP. The Court questioned why a medicine could carry an MRP several times higher than its actual supply price. The Court also examined the impact of inflated medicine bills under government-funded healthcare schemes. The burden of reimbursement under such schemes may ultimately fall on public funds. Corporate hospital pharmacy practices and patient choice were also discussed. The proceedings involve the regulatory framework applicable to scheduled and non-scheduled medicines. Generic medicines, medical devices and prescription practices are also part of the broader proceedings. The Court's remarks were made during a pending hearing and are not, by themselves, a final ruling declaring every high MRP or hospital medicine bill to be illegal. Frequently Asked Questions Can a hospital charge more than the price at which it purchased a medicine? A retailer or hospital may ordinarily have a margin between its purchase price and selling price, but the amount charged must comply with applicable law and pricing regulations. Whether a particular billing practice is unlawful depends on the facts. What is MRP in medicines? MRP means Maximum Retail Price. It is the maximum retail price printed on the packaged product, subject to the applicable legal framework. Why is there sometimes a large difference between medicine cost and MRP? The pricing structure can involve manufacturers, stockists, distributors and retailers. Different medicines are also subject to different regulatory mechanisms. The Supreme Court is examining concerns regarding substantial disparities in this pricing chain. Can patients demand medicines from an outside pharmacy? The answer may depend on the circumstances, hospital policies and applicable law. Where a hospital insists that medicines must be purchased only from its own pharmacy, the patient may seek clarification regarding the basis for such requirement and the applicable billing rules. What should I do if I believe a hospital has overcharged me for medicines? Keep the prescriptions, bills, medicine packaging and payment records. Ask the hospital for a detailed explanation and consider appropriate consumer or regulatory remedies depending on the facts. Does the Supreme Court's observation mean that all high-priced medicines involve fraud? No. The remarks were made during the hearing of pending petitions and concerned specific concerns about extreme price disparities and reimbursement under government schemes. They should not be treated as a blanket finding that every medicine sold at a high price constitutes fraud. Conclusion The Supreme Court's recent hearing has brought renewed attention to the issue of medicine pricing, MRP disparities and hospital pharmacy billing. The Court's questions focus on a fundamental concern: when a medicine is supplied at a substantially lower price but carries a significantly higher MRP, patients may face serious financial consequences, particularly where they have limited choice during medical treatment. The issue becomes even more significant when the cost is reimbursed under government healthcare schemes because public funds may ultimately bear the expense. At present, the matter remains pending, and further submissions are scheduled to be heard on 29 September 2026. The eventual directions of the Supreme Court will be important in determining whether changes are required in the existing framework governing medicine pricing and related healthcare practices. Case Details Case 1: Kishan Chand Jain v. Ethics and Medical Registration Board (EMRB) (Erstwhile Medical Council of India) & Others Case No.: W.P.(C) No. 794/2023 Diary No.: 25176/2023 Case 2: Dr. Sanjay Kulshresthra v. Union of India & Others Case No.: W.P.(C) No. 717/2026 Diary No.: 25121/2026 Court: Supreme Court of India Bench: Justice Vikram Nath and Justice Sandeep Mehta Further Hearing: 29 September 2026 SEO Keywords medicine price regulation, medicine MRP in India, medicine overcharging, hospital pharmacy charges, medicine price disparity, MRP of medicines, patient rights, medicine billing dispute, hospital billing, generic medicines in India, DPCO 2013, non-scheduled medicines, NPPA medicine price, legal rights of patients, healthcare consumer rights Meta Title Supreme Court Questions Medicine MRP and Hospital Pricing Practices Meta Description Supreme Court raises concerns over huge medicine price disparities, hospital pharmacy billing and reimbursement of inflated medicine costs under government health schemes. Suggested URL Slug supreme-court-medicine-mrp-price-disparity-hospital-billing Disclaimer: This article is intended for general legal awareness and informational purposes only. It does not constitute legal advice or create an advocate-client relationship. The Supreme Court proceedings discussed in this article are ongoing, and the Court's observations during a hearing should not be treated as a final determination of the legal issues.